凯普生物(300639) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the current period reached CNY 155,202,075.13, a year-on-year increase of 23.59%[7] - Net profit attributable to shareholders increased by 16.75% to CNY 32,225,676.90 for the current period[7] - Basic earnings per share rose by 15.84% to CNY 0.1777[7] - Total operating revenue for the period reached CNY 404,809,680.91, an increase from CNY 335,890,485.01 in the previous period, representing a growth of approximately 20.5%[47] - Net profit for the period was CNY 30,747,929.73, compared to CNY 26,839,506.27 in the same period last year, reflecting an increase of about 14.2%[40] - Earnings per share (EPS) for the period was CNY 0.1777, up from CNY 0.1534 in the previous period, indicating a growth of approximately 15.8%[41] - The company reported a total comprehensive income of CNY 32,626,124.79 for the period, compared to CNY 27,855,595.96 in the previous period, representing an increase of about 17.5%[41] - The company experienced an asset impairment loss of CNY 3,142,138.34, compared to CNY 2,018,433.30 in the previous period, indicating an increase of approximately 55.6%[47] Assets and Liabilities - Total assets increased by 9.30% to CNY 1,169,154,637.85 compared to the end of the previous year[7] - The company's total assets rose to ¥1,169,154,637.85, compared to ¥1,069,642,003.50 at the beginning of the period, reflecting a growth of 9.3%[33] - Non-current assets totaled ¥456,546,364.87, an increase from ¥372,390,577.16, indicating a growth of 22.6%[33] - The total liabilities decreased to ¥89,715,297.34 from ¥98,741,888.61, a reduction of 9.4%[33] - The equity attributable to shareholders of the parent company was ¥963,729,691.41, slightly up from ¥960,600,384.89, showing a marginal increase of 0.2%[33] Cash Flow - Cash flow from operating activities decreased by 29.03% to CNY 26,668,536.09 year-to-date[7] - The cash and cash equivalents decreased from 185.76 million yuan at the beginning of the period to 79.26 million yuan at the end of the period[30] - The net cash flow from operating activities for the current period is ¥112,232,502.52, compared to a negative cash flow of ¥19,586,279.36 in the previous period, indicating a significant improvement[57] - The total cash inflow from operating activities is ¥228,494,034.17, significantly higher than the previous period's inflow of ¥90,649,520.25[57] - The cash flow from financing activities shows a net outflow of -¥97,341,860.77, compared to a net inflow of ¥387,072,828.03 in the previous period[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,932[12] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 32.33% of the shares[12] - As of the report date, the company has repurchased 3,026,763 shares, totaling 52,523,031.62 yuan, accounting for 1.66% of the total share capital[19] - The maximum and minimum repurchase prices were 18.85 yuan/share and 15.55 yuan/share, respectively[19] Research and Development - R&D expenses increased by 32.75% compared to the same period last year, mainly due to increased R&D investment[17] - Research and development expenses amounted to CNY 31,288,192.37, compared to CNY 23,569,056.74 in the previous period, showing an increase of about 32.7%[47] - Research and development expenses increased significantly to ¥12,969,925.73, representing an increase of 79.5% compared to ¥7,222,515.81 in the previous year[38] Investment Income - Revenue from investment income increased by 113.54% compared to the same period last year, mainly due to increased cash management income[17] - Investment income for the period was CNY 6,522,985.85, compared to CNY 3,054,636.21 in the previous period, reflecting an increase of approximately 113.8%[47] - The company reported an increase in investment income to CNY 53,380,852.55 from CNY 3,054,636.21 in the previous year[51] Operating Costs - Total operating costs amounted to ¥123,390,832.55, up 27.1% from ¥96,988,140.38 year-over-year[38] - Total operating costs for the period were CNY 329,251,692.88, up from CNY 265,330,883.40, which is an increase of approximately 24.1%[47] - Management expenses increased by 30.22% compared to the same period last year, primarily due to increased office rental expenses[17] Other Financial Metrics - The company received government subsidies amounting to CNY 3,694,613.59 during the reporting period[10] - Other income for the period was CNY 3,694,613.59, down from CNY 5,586,145.30 in the previous period, indicating a decrease of about 33.9%[47] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[40]